

Stock Code: 4155

# OK Biotech Co., Ltd.

## 2026 Annual Shareholders Meeting

### Handbook



Convening Method: Physical Shareholder Meeting

Meeting Time: June 2, 2026 (Tuesday) 10:00 A.M.

Meeting Venue: No. 91, Sec.2, Gongdao 5th Rd., Hsinchu City

# Table of Contents

<input type="checkbox"/> Meeting Procedure	Page 1
<input type="checkbox"/> Meeting Agenda	Page 2
Report Items	Page 5
Recognized Items	Page 7
Discussion Items	Page 8
Extempore Motions	Page 9
<input type="checkbox"/> Attachments	
Attachment 1: 2025 Business Report	Page 10
Attachment 2: Audit Committee Review Report	Page 11
Attachment 3: Final Account Statement For Fiscal Year 2025	Page 12
Attachment 4: Report on the execution status of treasury share repurchase program.	Page 49
Attachment 5: 2025 Earning Distribution Table	Page 50
<input type="checkbox"/> Appendices	
Appendix 1: Shareholdings of All Directors	Page 51
Appendix 2: Articles of Incorporation	Page 52
Appendix 3: Rules And Procedure of Shareholder's Meeting	Page 61

# OK Biotech Company Limited

## **2026 Annual Shareholders Meeting**

### Meeting Procedure

- I. Call Meeting to Order
- II. Chairman's Address
- III. Report Items
- IV. Recognized Items
- V. Discussion Items
- VI. Extempore Motions
- VII. Adjournment

# OK Biotech Company Limited

## 2026 Annual Shareholders Meeting

### Meeting Agenda

Convening Method: Physical Shareholder Meeting  
Meeting Time: June 2, 2026 (Tuesday) 10:00 A.M.  
Meeting Venue: No. 91, Sec. 2, Gongdao 5th Rd., Hsinchu City

#### I. Call Meeting to Order

#### II. Chairman's Address

#### III. Report Items

1. Distribution of the Directors' Remuneration and the Employees' Compensation for the Fiscal Year 2025.
2. Business Report for the Fiscal Year 2025.
3. Audit Committee Review of the Financial Statements and Report for the Fiscal Year 2025.
4. The distribution of cash dividends from earnings for fiscal year 2025.
5. The issuance status of the third domestic unsecured convertible bonds.
6. The execution status of treasury share repurchase program.

#### IV. Recognized Items

1. 2025 Business Report and Financial Statements (consolidated and individual)
2. 2025 Earning Distribution

#### V. Discussion Items

1. Proposed cash capital reduction plan

#### VI. Extempore Motions

#### VII. Adjournment

## Report Items

### Report No. 1

**Proposed by the Board of Directors**

**Title:** Distribution of the Directors' Remuneration and the Employees' Compensation for the Fiscal Year 2025.

**Explanation:** In accordance with the Company's Articles of Incorporation, it is proposed to allocate directors' remuneration of NT\$2,063,998 and employees' remuneration of NT\$16,294,720 for fiscal year 2025, both to be distributed in cash. The aforementioned allocation amounts are consistent with the accruals recorded in the accounts for fiscal year 2025.

### Report No. 2

**Proposed by the Board of Directors**

**Title:** Business Report for the Fiscal Year 2025.

**Explanation:** The 2025 Business Report is attached as pp.[10], Attachment 1.

### Report No. 3

**Proposed by the Board of Directors**

**Title:** Audit Committee Review of the Financial Statements and Report for the Fiscal Year 2025.

**Explanation:**

1. The 2025 Audit Committee Review of the Financial Statements and Report is attached as Attachment 2 and pp.[12-48], Attachment 3
2. Kindly request the audit committee to present the review report.

### Report No. 4

**Proposed by the Board of Directors**

**Title:** The distribution of cash dividends from earnings for fiscal year 2025.

**Explanation:** On March 10, 2026, the Board of Directors resolved to distribute cash dividends of NT\$43,444,249 in accordance with the Company's Articles of Incorporation. While maintaining the dividend per share at NT\$0.3, should the total amount of cash dividends change prior to the ex-dividend date due to amendments by the competent authority or

changes in the Company's capital affecting the number of outstanding shares, the Chairman is authorized to handle such adjustments with full discretion.

**Report No. 5**

**Proposed by the Board of Directors**

**Title:** The issuance status of the third domestic unsecured convertible bonds.

**Explanation:**

1. As of the year ended December 2022, the Company issued third domestic unsecured convertible corporate bonds with a total issuance amount of NT\$300,000 thousand. Each bond has a face value of NT\$100,000. The issuance was made at par value, totaling 3,000 bonds, with a coupon rate of 0% and a three-year maturity period, raising a total of NT\$300,000 thousand in funds.
2. The Company's third domestic unsecured convertible bonds matured on September 28, 2025. For bondholders who did not complete conversion, the Company completed repayment of the principal on October 9, 2025.

**Report No. 6**

**Proposed by the Board of Directors**

**Title:** The execution status of treasury share repurchase program.

**Explanation:** At the 8th Board of Directors' 5th meeting on April 10, 2025, and the 8th meeting on August 21, 2025, the Board resolved to approve the share repurchase program. The program has been duly executed and completed. Please refer to Attachment 4, page 49.

## Recognized Items

### Report No. 1

### Proposed by the Board of Directors

**Title:** 2025 Business Report and Financial Statements (consolidated and individual),

**Explanation:** 1. The financial statements (consolidated and parent company only) of the Company for the year ended December 31, 2025 audited by Ms. Tsai-Yen Chiang and Mr. Cheng-Han Jiang, certified public accountants of PwC Taiwan, have been completed. The draft audit report, along with the business report, was approved by the Board of Directors on March 10, 2026, and the auditor's report was issued on the same day. Please refer to pp.[10~48] Attachment 1~3.

2. Please recognize the submitted documents.

### Resolution:

### Report No. 2

### Proposed by the Board of Directors

**Title:** 2025 Earning Distribution.

**Explanation:** 1. For fiscal year 2025, the Company recorded net income after tax of NT\$82,449,195 and undistributed earnings of NT\$36,408,124. After deducting NT\$19,738,600 from disposal of financial assets measured at fair value through other comprehensive income, NT\$2,749,178 from cancellation of treasury shares, and appropriating 10% statutory legal reserve of NT\$5,996,142, it is proposed, in accordance with the Articles of Incorporation, to distribute shareholders' dividends of NT\$43,444,249. Please refer to the Earnings Distribution Table for fiscal year 2025 in Attachment 5, page 35. All dividends are to be distributed in cash.

2. The cash dividend distribution for fiscal year 2025 is temporarily calculated based on 144,814,164 shares, the number of shares registered with the Ministry of Economic Affairs as of March 2, 2026. While maintaining the dividend per share at NT\$0.3, should the total cash dividend amount change prior to the ex-dividend date due to amendments by the competent authority or changes in

the Company's capital affecting the number of outstanding shares, the Chairman is authorized to handle such adjustments with full discretion.

3. The cash dividend distribution is calculated by rounding down to the nearest whole NT dollar. Fractional shares less than NT\$1 will be adjusted in sequence according to decimal digits from largest to smallest and by shareholder account number order, until the total cash distribution amount is consistent.
4. The ex-dividend date and payment date shall be determined by the Chairman as authorized by the Board of Directors.
5. Please recognize the submitted documents.

**Resolution:**

## **Discussion Items**

### **Report No. 1**

### **Proposed by the Board of Directors**

**Title:** Proposed cash capital reduction plan

**Explanation:**

1. To adjust the capital structure and enhance shareholders' return on equity, the Company proposes to conduct a cash capital reduction to return funds to shareholders.
2. The proposed cash capital reduction amount is NT\$144,814,160, with 14,481,416 shares to be cancelled. Based on the current total issued ordinary shares of 144,814,164, the reduction ratio is approximately 10%. Each share will be refunded NT\$1.00 in cash, rounded down to the nearest whole NT dollar. After the reduction, the share capital will be NT\$1,303,327,480, comprising 130,332,748 shares. However, the actual paid-in capital and reduction ratio shall be calculated based on the total issued shares on the record date of the capital reduction.
3. Based on the current issued shares, approximately 100 shares will be reduced for every 1,000 shares held (i.e., 900 shares will be issued for every 1,000 shares). Fractional shares resulting from the reduction may be consolidated into whole shares by shareholders through the Company's share transfer agent prior to the suspension of share transfers. Any remaining fractional shares that cannot be consolidated will be settled in cash based on the closing price of the last trading day on the public centralized market prior to the

record date of the capital reduction, rounded down to the nearest NT dollar. The Chairman is authorized to arrange for specific parties to purchase such fractional shares at the closing price.

4. The new shares issued from this cash capital reduction will be in dematerialized form, with rights and obligations identical to the original shares. Upon approval by the shareholders' meeting and effectiveness of filing with the competent authority, the Chairman is authorized to determine the share exchange plan, the record date of the capital reduction, and the record date for issuance of new shares.
5. If, prior to the record date of the capital reduction, changes in the Company's capital affect the number of outstanding shares, thereby requiring adjustments to the reduction ratio or per-share refund amount, or if amendments are necessitated by changes in laws, regulatory approval, or other objective circumstances, the shareholders' meeting shall authorize the Chairman to handle such matters with full discretion.
6. Please vote for public approval.

**Resolution:**

**Extempore Motions**

**Adjournment**

**OK Biotech Company Limited**  
**2025 Business Report**

## I. Results of Business Plan Implementation

For the year ended December 31, 2024, the Company's operating revenue amounted to NT\$1,556,295, net gross profit was NT\$429,251, operating expenses were NT\$321,357, operating income was NT\$107,894, net profit before tax was NT\$103,867, net profit after tax was NT\$97,130, other comprehensive income was NT\$944, total comprehensive income was NT\$98,074, and earnings per share after tax were NT\$0.58.

(In Thousands of New Taiwan Dollars)

Item	2025	2024	Increase (Decrease) Rate (%)
Operating revenue	\$1,556,295	\$1,670,033	(6.81%)
Operating cost	(1,127,044)	(1,394,378)	(19.17%)
Net gross profit (loss) from operations	429,251	281,948	52.24%
Operating expenses	(321,357)	(224,735)	42.99%
Operating profit	107,894	57,213	88.58%
Net non-operating income and expenses	(4,027)	69,897	(105.76%)
Net profit before tax	103,867	127,110	(18.29%)
Net profit after tax	97,130	106,319	(8.64%)
Other comprehensive income	944	3,908	(75.84%)
Total comprehensive income	98,074	110,227	(11.03%)

## II. Analysis of Financial Balance and Profitability

(In Thousands of New Taiwan Dollars)

Analysis Item		2025	2024	
Financial Balance	Operating revenue	1,556,295	1,670,033	
	Operating cost	(1,127,044)	(1,394,378)	
	Net profit after tax	97,130	106,319	
Profitability	Return on shareholders' equity (%)	3.77%	4.14%	
	Ratio to paid-in capital (%)	Operating profit	7.45%	3.89%
		Net profit before tax	7.17%	8.64%
	Net profit rate (%)	6.24%	6.37%	
Earnings per share (in NT\$)	0.58	0.66		

## III. Statement of Research and Development

## Details of Research and Development Expenditures in the Last Two Years

(In Thousands of New Taiwan Dollars)

	2025	2024
R&D expenses	\$ 59,042	\$ 57,927
Operating revenue	1,556,295	1,670,033
Proportion (%)	3.79	3.47

Chairman

Manager

Accountant Supervisor

**OK Biotech Co., Ltd.**

**Audit Committee Review Report**

The Board of Directors submitted the 2025 Annual Operating Report Individual Financial Statements, and Consolidated Financial Statements (including balance sheets, comprehensive income statements, equity movement statements, and cash flow statements, etc.) to the company. After being audited and reviewed by Ms. Tsai-Yen Chiang and Mr. Cheng-Han Jiang, the joint certified public accountants appointed by the company, they believe that it is sufficient to express the financial status, operating results, and cash flow situation of the company, and issued a financial report. The above books and reports have been reviewed by the audit committee and deemed compliant, and therefore reported in accordance with Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act. Please review it for approval.

To:

OK Biotech Company Limited

OK Biotech Company Limited

Convenor of the Audit Committee: Chen, Ku-Chuan

March 10, 2026

OK Biotech Company Limited  
Representation Letter

The entities included in the combined financial statements of OK Biotech Company Limited for the year ended December 31, 2025 (January 1, 2025, to December 31, 2025), as required under the Criteria Governing the Preparation of Affiliation Reports, Consolidated Business Reports, and Consolidated Financial Statements of Affiliated Enterprises, are identical to those included in the consolidated financial statements prepared in accordance with IFRS 10 Consolidated Financial Statements. Furthermore, all information required to be disclosed in the combined financial statements is already presented in the consolidated financial statements. Therefore, OK Biotech Company Limited and its subsidiaries have not prepared a separate set of combined financial statements.

Very truly yours,

Company Name: OK Biotech Co., Ltd.

Chairman: Lai, Chia-De

March 10, 2026

## Independent Auditor's Report

(115) Cai-Sen-Bao- 25004852

To the Board of Directors and Shareholders of OK Biotech Company Limited

### **Opinion**

We have audited the accompanying consolidated financial statements of OK Biotech Company Limited and Subsidiaries (the "Company"), which comprise the consolidated balance sheets as of December 31, 2025, and 2024, and the consolidated statements of comprehensive income, changes in equity, and cash flows for the years then ended. Additionally, we have audited the accompanying notes to the consolidated financial statements, which include a summary of significant accounting policies and other explanatory information.

Based on the results of our audit and the audit reports of other auditors (please refer to the Other Matters paragraph), in our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025, and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations, and SIC Interpretations, as endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

### **Basis for Opinion**

We conducted our audit in accordance with the Regulations Governing the Audit and Attestation of Financial Statements by Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the section Auditors' Responsibilities for the Audit of the Consolidated Financial Statements. The personnel of our firm subject to independence requirements have maintained independence from OK Biotech Group in accordance with the Norm of Professional Ethics for Certified Public Accountants of the Republic of China, and have fulfilled other ethical responsibilities under such requirements. Based on our audit results and the audit reports of other auditors, we believe that we have obtained sufficient and appropriate audit evidence to provide a basis for our audit opinion.

### **Key Audit Matters**

Key audit matters are those that, in our professional judgment, were most significant in auditing the consolidated financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon. We do not provide a separate opinion on these matters.

Key audit matters for the Company's consolidated financial statements for the year ended December 31, 2025, are stated as follows:

## **Intangible Assets - Impairment of Goodwill**

### Explanation of Matters

For details regarding the accounting policies of impairment assessments of goodwill and non-financial assets, please refer to Notes 4 (17) and 4 (19). For details on the impairment assessment of goodwill, please refer to Notes 6 (10) and 6 (11) of the consolidated financial statements. For a description of accounting estimates and assumptions, please refer to Note 5.

The goodwill of Prodigy Diabetes Care, LLC, a subsidiary held by the OK Biotech Group, amounts to NT\$329,889 thousand. The recoverable amount of the goodwill is assessed based on its value in use, which is determined by estimating the future cash flows expected to be generated, based on the financial budgets prepared by management, including estimates of future revenues and expenses. These cash flows are discounted using an appropriate discount rate to assess whether the goodwill is impaired. Given that this estimation involves various assumptions such as determining discount rates, expected growth rates, and future financial budgets, it is subject to subjective judgment and uncertainty, leading to significant impacts on the measurement of recoverable amounts. Therefore, we consider the impairment assessment of goodwill as one of the key audit matters.

### Audit Procedures Undertaken

Our auditors have executed the following audit procedures:

1. Reviewed the reasonableness of the valuation methods employed in the assessment reports of external experts.
2. Assessed the reasonableness of using revenue growth rates and gross profit margins and compared them with historical results.
3. Evaluated the parameters of discount rates used, including weighted average cost of capital, return on assets, and risk-free rates.

## **Acquisition Transactions**

### Explanation of Matters

Regarding the accounting policy for revenue recognition, please refer to Note 4 (32) of the consolidated financial statements for detailed explanations on revenue recognition. For details on revenue items, please refer to Note 6 (25) of the consolidated financial statements.

The Company's sales are distributed among customers in Taiwan, Asia, the Americas, and Africa, among other countries. With a large and diverse customer base, transaction terms vary depending on market conditions and customer needs. Considering that sales revenue is a significant aspect of the Company's transactions, has a major impact on the financial statements, and requires substantial time and resources for verification, we have identified the validity of sales revenue as one of the key audit matters for the current audit.

### Audit Procedures Undertaken

Our auditors have executed the following audit procedures, among others:

We assessed the reasonableness of management's recognition and measurement of the fair value of identifiable net assets acquired in the transaction. This evaluation included, among other evidence, the purchase price allocation report provided by external experts. Additionally, we reviewed the key assumptions used in the recognition process, which were independently verified by internal experts, to ensure the fair value of the identifiable net assets was reasonable.

### **Sales Revenue Validity**

#### Explanation of Matters

Regarding the accounting policy for revenue recognition, please refer to Note 4 (32) of the consolidated financial statements for detailed explanations on revenue recognition. For details on revenue items, please refer to Note 6 (25) of the consolidated financial statements.

The Company's sales are distributed among customers in Taiwan, Asia, the Americas, and Africa, among other countries. With a large and diverse customer base, transaction terms vary depending on market conditions and customer needs. Considering that sales revenue is a significant aspect of the Company's transactions, has a major impact on the financial statements, and requires substantial time and resources for verification, we have identified the validity of sales revenue as one of the key audit matters for the current audit.

#### Audit Procedures Undertaken

Our audit procedures related to the sales revenue validity included the following, among others:

1. Evaluated the appropriateness of the revenue recognition accounting policy.
2. Assessed and tested the internal control system and actual process execution for sales transactions.
3. Conducted substantive tests of transactions for sales revenue transactions. These tests involved verification of documentation related to recognizing sales revenue, examination of transaction terms, performance obligations, and transaction prices to confirm the occurrence of transactions, and execution of accounts receivable collection procedures.

## **Other Matters: Reference to the Audit of Other Auditors**

Certain subsidiaries and equity-method investees included in the consolidated financial statements of Hsun Ying Optoelectronics Co., Ltd. for the years ended December 31, 2025 and 2024 were audited by other auditors rather than by us. Accordingly, with respect to the amounts included in the consolidated financial statements relating to such subsidiaries, our opinion is based solely on the reports of those other auditors. As of December 31, 2025 and 2024, the total assets of these subsidiaries amounted to NT\$113,691 thousand and NT\$147,215 thousand, representing 2.95% and 3.98% of consolidated total assets, respectively; their total liabilities amounted to NT\$54,420 thousand and NT\$84,773 thousand, representing 4.28% and 7.51% of consolidated total liabilities, respectively. For the years ended December 31, 2025 and 2024, their operating revenues included in the consolidated statements of comprehensive income amounted to NT\$60,829 thousand and NT\$29,836 thousand, representing 3.91% and 1.79% of consolidated operating revenues, respectively. In addition, the balances of long-term equity investments accounted for under the equity method as of December 31, 2025 and 2024 were NT\$10,662 thousand and NT\$10,870 thousand, representing 0.28% and 0.29% of consolidated total assets, respectively; and the share of comprehensive income (loss) recognized for the years ended December 31, 2025 and 2024 amounted to NT\$578 thousand and (NT\$918 thousand), representing 0.59% and (0.83%) of consolidated comprehensive income, respectively.

## **Other Matters: Parent Company Only Financial Statements**

The Company has prepared individual financial statements for the years ended December 31, 2025, and 2024, and we have issued an unqualified audit report with an emphasis of matter paragraph. These financial statements are available for reference.

## **Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, Interpretations, and Pronouncements approved and enacted by the Financial Supervisory Commission. Management is also responsible for maintaining the necessary internal controls related to the preparation of the consolidated financial statements to ensure that they are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is also responsible for assessing the Company's ability to continue as a going concern, disclosing relevant matters, and adopting the going concern basis of accounting, unless management intends to liquidate the Company, cease operations, or has no realistic alternative but to do so.

Those charged with governance (including members of the Audit Committee) are responsible for overseeing the Company's financial reporting process.

## **Auditors' Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements may arise due to fraud or error. A misstatement is considered material if it could reasonably be expected to influence the economic decisions of users taken based on the consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also performed the following procedures:

1. Identified and assessed the risks of material misstatement in the consolidated financial statements due to fraud or error; designed and performed appropriate responses to the assessed risks; and obtained sufficient and appropriate audit evidence to form the basis for the audit opinion. The risk of a material misstatement due to fraud was higher than that due to error, as fraud may involve collusion, forgery, deliberate omission, misrepresentation, or circumvention of internal controls.
2. Obtained an understanding of internal control relevant to the audit in order to design audit procedures that were appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluated the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Concluded on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty existed related to events or conditions that may have cast significant doubt on the Company's ability to continue as a going concern. If we concluded that a material uncertainty existed, we were required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures were inadequate, to modify our opinion. Our conclusions were based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluated the overall presentation, structure, and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represented the underlying transactions and events in a manner that achieved fair presentation.

6. Obtained sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We were responsible for the direction, supervision and performance of the audit. We remained solely responsible for our audit opinion.

We communicated with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit.

We also provided those charged with governance with a statement that the personnel of our firm, subject to independence regulations, had complied with the independence requirements outlined in the Code of Ethics for Professional Accountants of the Republic of China, and communicated with them all relationships and other matters that may reasonably be thought to affect our independence, including related safeguards.

Based on matters communicated with those charged with governance, we determined the key audit matters for the audit of the Company's consolidated financial statements for the year 2024. In the audit report, we disclosed these matters, unless the law prohibited the disclosure of certain matters or, in extremely rare circumstances, we decided not to communicate certain matters in the audit report because we reasonably expected that the negative consequences of such communication would outweigh the public interest that would be served.

PwC Taiwan

Chiang Tsai-Yen

CPA:

Jiang Cheng-Han

Financial Supervisory Commission Approval

No. of Certification: Jin-Guan-Zheng-Shen-Zi No. 1060025097

Former Executive Yuan Financial Supervisory Commission,  
Securities and Futures Bureau, Approval

No. of Certification: Jin-Guan-Zheng-Liu-Zi No. 1130350413

March 10, 2026

**OK Biotech Company Limited and Subsidiaries**  
**CONSOLIDATED BALANCE SHEETS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

(In Thousands of New Taiwan Dollars)

	Assets	Note	December 31, 2025		December 31, 2024	
			Amount	%	Amount	%
	<b>Current assets</b>					
1100	Cash and cash equivalents	6 (1)	\$ 314,473	8	\$ 277,458	8
1110	Financial assets at fair value through profit or loss	6 (2)				
	- Current		12,586	-	13,042	-
1150	Net amount of notes receivable	6 (4)	2,374	-	1,460	-
1170	Net amount of accounts receivable	6 (4)	380,626	10	558,723	15
1180	Net amount of accounts receivable from related parties	6 (4) & 7	115	-	4	-
1200	Other receivables		3,031	-	10,640	-
1210	Other receivables from related parties	7	-		687	
1220	Income tax assets		23,690	1	16,984	1
130X	Inventories	6 (5)	456,003	12	530,535	14
1410	Prepayments		54,928	1	62,345	2
1470	Other current assets		1,427	-	787	-
11XX	<b>Total current assets</b>		<u>1,249,253</u>	<u>32</u>	<u>1,472,665</u>	<u>40</u>
	<b>Non-current assets</b>					
1517	Financial assets at fair value through other comprehensive income - Non-current	6 (3)	12,701	1	11,369	-
1550	Investments accounted for using equity method	6 (7)	10,662	-	10,870	-
1600	Property, plant and equipment	6 (8) & 8	1,927,227	50	1,590,878	43
1755	Right-of-use assets	6 (9)	101,090	3	36,317	1
1780	Intangible assets	6 (10)	465,081	12	478,487	13
1840	Deferred tax assets and liabilities	6 (32)	72,002	2	62,340	2
1900	Other non-current assets	6 (6) & 8	11,408	-	32,393	1
15XX	<b>Total non-current assets</b>		<u>2,600,171</u>	<u>68</u>	<u>2,222,654</u>	<u>60</u>
1XXX	<b>Total assets</b>		<u>\$ 3,849,424</u>	<u>100</u>	<u>\$ 3,695,319</u>	<u>100</u>

(Next page)

**OK Biotech Company Limited and Subsidiaries**  
**CONSOLIDATED BALANCE SHEETS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

(In Thousands of New Taiwan Dollars)

Liabilities and Equities	Note	December 31, 2025		December 31, 2024		
		Amount	%	Amount	%	
<b>Current liabilities</b>						
2100	Short-term loans	6 (12)	\$ 295,000	8	\$ 305,000	8
2120	Financial liabilities at fair value through profit or loss - Current	6 (13)	-	-	653	-
2130	Contracts liabilities - Current	6 (25)	23,040	1	48,439	1
2150	Notes payable	6 (35)	20,832	2	59,383	2
2170	Accounts payable	6 (14)	64,941	2	137,731	4
2180	Accounts payable from related parties	6 (14) & 7	51,494	2	57,662	2
2200	Other payables	6 (15) & 7	67,092	2	61,625	2
2230	Income tax liabilities		2,239	-	11,872	-
2280	Lease liabilities - Current		10,740	-	3,818	-
2320	Long-term loans due within one year or one operating cycle	6 (17) (18) & 8	10,185	1	55,462	1
2399	Other current liabilities - Other		2,038	-	3,119	-
21XX	<b>Total current liabilities</b>		<u>547,601</u>	<u>14</u>	<u>744,764</u>	<u>20</u>
<b>Non-current liabilities</b>						
2540	Long-term loans	6 (18) & 8	606,464	16	321,996	9
2550	Provisions – Non-current	6 (16)	3,300	-	-	-
2570	Deferred tax liabilities	6 (32)	25,165	1	27,847	1
2580	Lease liabilities - Non-current		90,762	2	33,771	1
2600	Other non-current liabilities		24	-	24	-
25XX	<b>Total non-current liabilities</b>		<u>725,715</u>	<u>19</u>	<u>383,638</u>	<u>11</u>
2XXX	<b>Total liabilities</b>		<u>1,273,316</u>	<u>33</u>	<u>1,128,402</u>	<u>31</u>
<b>Equity</b>						
	Capital share	6 (21)				
3110	Capital share - Common share		1,448,142	40	1,470,592	40
	Capital surplus	6 (22)				

(Next page)

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)  
(Except Earnings per Share in NT\$)

	Liabilities and Equities	Note	December 31, 2025		December 31, 2024	
			Amount	%	Amount	%
3200	Capital surplus		885,197	23	890,594	24
	Retained earnings	6 (23)				
3310	Legal capital reserve		147,425	4	138,478	4
3320	Special capital reserve		19,581	-	19,580	-
3350	Undistributed earnings		96,695	2	89,471	2
	Other equity	6 (24)				
3400	Other Equity		( 83,858 )	( 2 )	( 116,642 )	( 3 )
31XX	<b>Total equity attributed to shareholders of the parent</b>		2,513,182	65	2,492,073	67
36XX	<b>Non-controlling interests</b>		62,926	2	74,844	2
3XXX	<b>Total equity</b>		2,576,108	67	2,566,917	69
	Significant contingent liabilities and unrecognized commitments	9				
	Significant subsequent events	11				
3X2X	<b>Total liabilities and equities</b>		\$ 3,849,424	100	\$ 3,695,319	100

(Next page)

**OK Biotech Company Limited and Subsidiaries**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

(In Thousands of New Taiwan Dollars)  
(Except Earnings per Share in NT\$)

Item	Note	2025		2024		
		Amount	%	Amount	%	
4000	Operating revenue	6 (25) & 7	\$ 1,556,295	100	\$ 1,670,033	100
5000	Operating cost	6 (5) (30) (31)	( 1,127,044 )	( 72 )	( 1,394,378 )	( 83 )
5900	Gross profit (loss) from operations		429,251	28	275,655	17
5910	Unrealized profit (loss) from sales	6 (7)	-	-	-	-
5920	Realized profit (loss) from sales	6 (7)	-	-	6,293	-
5950	Net gross profit (loss) from operations		429,251	17	281,948	17
	Operating expenses	6 (30) (31)				
6100	Marketing		( 91,457 )	( 6 )	( 78,388 )	( 5 )
6200	General and administrative		( 159,614 )	( 10 )	( 98,865 )	( 6 )
6300	Research and development		( 59,042 )	( 4 )	( 57,927 )	( 3 )
6450	Gain (loss) on expected credit losses	12 (2)	( 11,244 )	( 1 )	10,445	1
6000	Total operating expenses		( 321,357 )	( 21 )	( 224,735 )	( 13 )
6900	Net operating income (loss)		107,894	7	57,213	4
	Non-operating income and expenses					
7100	Interest income	6 (26)	3,423	-	6,096	-
7010	Other income	6 (27) & 7	25,749	2	19,914	1
7020	Other gains and losses	6 (28)	( 22,857 )	( 1 )	45,006	3
7050	Finance costs	6 (29) & 7	( 10,920 )	( 1 )	( 6,230 )	-
7060	Share of profit (loss) of associates and joint ventures accounted for using equity method	6 (7)	578	-	5,111	-
7000	Total non-operating income and expenses		( 4,027 )	-	69,897	4
7900	<b>Net profit before tax</b>		103,867	7	127,110	8
7950	Income tax expenses	6 (32)	( 6,737 )	( 1 )	( 20,791 )	( 1 )
8200	<b>Net profit (loss)</b>		\$ 97,130	6	\$ 106,319	7

**OK Biotech Company Limited and Subsidiaries**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

(In Thousands of New Taiwan Dollars)  
(Except Earnings per Share in NT\$)

Item	Note	2025		2024	
		Amount	%	Amount	%
<b>Other comprehensive income (loss), net of income tax</b>					
<b>Items that will not be reclassified subsequently to profit or loss:</b>					
8316	Unrealized profits (losses) on equity investments at fair value through other comprehensive income	6 (3) (23)			
		\$ 1,332	-	\$ 250	-
8310	Total items that will not be reclassified subsequently to profit or loss	1,332	-	250	-
<b>Items that may be reclassified subsequently to profit or loss</b>					
8361	Exchange differences arising on translation of foreign operating entity	6 (23)	-	4,573	-
8399	Income tax relating to items that may be reclassified	6 (23) (31)	-	( 915 )	-
8360	Items that may be reclassified subsequently to profit or loss	( 388 )	-	3,658	-
8300	<b>Other comprehensive income (loss), net of income tax</b>	\$ 944	-	\$ 3,908	-
8500	<b>Total comprehensive income</b>	\$ 98,074	6	\$ 110,227	7
Net income attributable to:					
8610	Shareholders of the parent	\$ 82,449	5	\$ 93,975	6
8620	Non-controlling interests	\$ 14,681	1	\$ 12,344	1
Total comprehensive income attributable to:					
8710	Shareholders of the parent	\$ 83,517	5	\$ 97,883	6
8720	Non-controlling interests	\$ 14,557	1	\$ 12,344	1
Basic earnings per share					
9750	Net profit	6 (32)	0.58	0.66	
Diluted earnings per share					
9850	Net profit	6 (32)	0.57	0.64	

Attached are the notes to the consolidated financial statements, which form an integral part of this consolidated financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

Note	Equity Attributed to Owners of Parent												
	Capital Share - Common Share	Capital Surplus			Retained Earnings				Other equity	Treasury Shares	Total	Non-controlling Interests	Total Equity
		Capital Surplus - Premium on Issuance	Capital Surplus - Restricted Stock	Capital Surplus - Others	Legal Capital Reserve	Special Capital Reserve	Undistributed Earnings						
<u>2024</u>													
Balance, January 1, 2024	\$ 1,457,698	\$ 858,544	\$ 57,800	\$ 5,942	\$ 138,466	\$ 19,464	\$ 128	(\$ 140,193 )	\$ -	\$ 2,397,849	(\$ 2,755 )	\$ 2,395,094	
Net profit	-	-	-	-	-	-	93,975	-	-	93,975	12,344	106,319	
Other comprehensive income													
Other comprehensive income	-	-	-	-	-	-	-	3,908	-	3,908	-	3,908	
Total comprehensive income	-	-	-	-	-	-	93,975	3,908	-	97,883	12,344	110,227	
Appropriation and distribution of retained earnings for the year ended 2023													
Recognition of legal capital reserve	-	-	-	-	12	-	( 12 )	-	-	-	-	-	
Recognition of special capital reserve	-	-	-	-	-	116	( 116 )	-	-	-	-	-	
Cash distribution from capital surplus	-	( 44,118 )	-	-	-	-	-	-	-	( 44,118 )	-	( 44,118 )	
Cancellation of employee-restricted shares	( 610 )	-	610	-	-	-	-	-	-	-	-	-	

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

Note	Equity Attributed to Owners of Parent												
	Capital Share - Common Share	Capital Surplus - Premium on Issuance	Capital Surplus - Restricted Stock	Capital Surplus - Others	Legal Capital Reserve	Special Capital Reserve	Undistributed Earnings	Other equity	Treasury Shares	Total	Non-controlling Interests	Total Equity	
Transfer of corporate	6 (17) (21)												
bonds		13,504	12,138	- ( 322 )	-	-	-	-	-	25,320	-	25,320	
Vesting of	6 (20)												
employee-restricted													
newly issued shares		-	58 ( 58 )	-	-	-	-	-	-	-	-	-	
Compensation expense	6 (20)(24)												
for restricted shares													
granted to employees		-	-	-	-	-	-	19,643	-	19,643	-	19,643	
Non-proportional													
subscription of newly													
issued shares by													
subsidiary		-	-	-	-	-	( 4,504 )	-	-	( 4,504 )	4,504	-	
Increase in	6 (3) (24)												
non-controlling interests		-	-	-	-	-	-	-	-	-	60,751	6075	
Balance, December 31,													
2024		\$ 1,470,592	\$ 826,622	( \$ 58,352	\$ 5,620	\$ 138,478	\$ 19,580	\$ 89,471	( \$ 116,642 )	\$ -	\$ 2,492,073	\$ 74,844	\$ 2,566,917

(Next page)

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

Note	Equity Attributed to Owners of Parent												
	Capital Share - Common Share	Capital Surplus			Retained Earnings				Other equity	Treasury Shares	Total	Non-controlling Interests	Total Equity
		Capital Surplus - Premium on Issuance	Capital Surplus - Restricted Stock	Capital Surplus - Others	Legal Capital Reserve	Special Capital Reserve	Undistributed Earnings						
<u>2025</u>													
Balance, January 1, 2025	\$ 1,470,592	\$ 826,622	\$ 58,352	\$ 5,620	\$ 138,478	\$ 19,580	\$ 89,471	(\$ 140,193)	\$ -	\$ 2,492,073	\$ 74,844	\$ 2,566,917	
Net profit	-	-	-	-	-	-	82,449	-	-	82,449	14,681	97,130	
Other comprehensive income	6 (24)	-	-	-	-	-	-	1,068	-	1,068	( 124 )	944	
Total comprehensive income													
income	-	-	-	-	-	-	82,449	1,068	-	83,517	14,557	98,074	
Appropriation and distribution of retained earnings for the year ended 2024	6 (23)												
Cash dividend	-	-	-	-	-	-	( 43,789 )	-	-	( 43,789 )	-	( 43,789 )	
Recognition of legal capital reserve	-	-	-	-	8,947	-	( 8,947 )	-	-	-	-	-	
Recognition of special capital reserve	-	-	-	-	-	1	( 1 )	-	-	-	-	-	
Issuance of employee-restricted	6 (20)	-	1,750	963	-	-	-	( 2,713 )	-	-	-	-	

Attached are the notes to the consolidated financial statements, which form an integral part of this consolidated financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

Note	Equity Attributed to Owners of Parent											
	Capital Share - Common Share	Capital Surplus - Premium on Issuance	Capital Surplus - Restricted Stock	Capital Surplus - Others	Legal Capital Reserve	Special Capital Reserve	Undistributed Earnings	Other equity	Treasury Shares	Total	Non-controlling Interests	Total Equity
newly issued shares												
Cancellation of employee-restricted shares	6 (20)	( 4,200 )	-	-	4,200	-	-	-	-	-	-	-
Compensation expense for restricted shares granted to employees	6 (20) (24)	-	-	-	-	-	-	14,690	-	14,690	-	14,690
Cash dividends distributed by subsidiaries to non-controlling interests		-	-	-	-	-	-	-	-	-	( 26,475 )	( 26,475 )
Disposal of financial assets measured at fair value through FVOCI	6 (3) (24)	-	-	-	-	-	( 19,739 )	19,739	-	-	-	-
Repurchase of treasury shares	6 (21)	-	-	-	-	-	-	-	( 33,309 )	( 33,309 )	-	( 33,309 )
Cancellation of treasury shares	6 (21)	( 20,000 )	( 10,500 )	-	( 60 )	-	( 2,749 )	-	33,309	-	-	-

Attached are the notes to the consolidated financial statements, which form an integral part of this consolidated financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

Note	Equity Attributed to Owners of Parent												
	Capital Share - Common Share	Capital Surplus			Retained Earnings				Other equity	Treasury Shares	Total	Non-controlling Interests	Total Equity
		Capital Surplus - Premium on Issuance	Capital Surplus - Restricted Stock	Capital Surplus - Others	Legal Capital Reserve	Special Capital Reserve	Undistributed Earnings						
Balance, December 31,													
2025	\$ 1,448,142	\$ 816,122	\$ 59,315	\$ 9,769	\$ 147,425	\$ 19,518	\$ 96,695	( \$ 83,858 )	\$ -	\$ 2,513,182	\$ 62,926	\$ 2,576,108	

Attached are the notes to the consolidated financial statements, which form an integral part of this consolidated financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

**OK Biotech Company Limited and Subsidiaries**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

(In Thousands of New Taiwan Dollars)

	Note	December 31, 2025	December 31, 2024
<b>Statement of Cash Flows from Operating Activities</b>			
Pre-tax net income for the period		\$ 103,867	\$ 127,110
Adjustments for:			
Income and expense			
Depreciation expense	6 (8) (9) (30)	79,959	67,196
Amortization expense	6 (10) (30)	13,653	5,226
Interest expense	6 (29)	10,920	6,230
Interest income	6 (26)	( 3,423 )	( 6,096 )
Losses (gains) on expected credit losses	12 (2)	11,244	( 10,445 )
Net (profit) loss from financial assets and liabilities at fair value through profit or loss	6 (2) (13) (28)	( 197 )	2,962
Profits on lease modification	6 (27)	-	( 79 )
Share-based cost for compensation	6 (20) (31)	14,690	19,643
Share of profit (loss) of associates and joint ventures accounted for using equity method	6 (7)	( 578 )	( 5,111 )
Profit (loss) on disposal of investments	6 (28)	( 1,214 )	4,003
Profits on disposal of property, plant, and equipment	6 (28)	( 2,963 )	( 2,310 )
Unrealized (realized) gains/losses on transactions with associated companies	6 (8)	-	( 6,293 )
Changes in operating assets/liabilities			
Net changes in operating assets			
Net changes in financial assets at fair value through profit or loss		-	26,276
Notes receivable		( 914 )	1,608
Notes receivable from related parties		-	208
Accounts receivable		165,557	( 159,140 )
Accounts receivable from related parties		( 111 )	117,218
Other receivables		7,581	367
Inventories		70,834	( 41,143 )
Prepayments		7,249	2,257
Other current assets		( 640 )	4,120
Other non-current assets		( 4,170 )	( 1,166 )
Net changes in operating liabilities			
Contracts liabilities		( 25,399 )	( 41,879 )
Notes payable		( 708 )	1,037
Accounts payable		( 71,531 )	( 73,208 )
Accounts payable from related parties		( 6,168 )	( 7,535 )
Other payables		( 8,937 )	17,626
Other current liabilities		( 1,081 )	( 8,692 )
Non-current provisions		3,300	-
Cash inflow generated from operation		360,820	39,990
Interest received		3,423	6,096

(Next page)

**OK Biotech Company Limited and Subsidiaries**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

(In Thousands of New Taiwan Dollars)

	Note	December 31, 2025	December 31, 2024
Dividends received	6 (7)	-	16,022
Interest paid		( 10,112 )	( 5,193 )
Income taxes refunded		-	17,173
Income taxes paid		( 35,271 )	( 8,185 )
Net cash inflow generated from operation		<u>318,860</u>	<u>65,903</u>
<b><u>Cash Flows from Investing Activities</u></b>			
Disposal of financial assets measured at amortized cost		\$ -	\$ 30,000
Acquisition of financial assets at fair value through other comprehensive income	6 (3) & 12 (3)	-	( 1,243 )
Acquisition of subsidiary, net of cash acquired	6 (7)	-	( 136,914 )
Disposal of equity method investments	6 (7)	2,000	3,500
Acquisitions of property, plant and equipment	6 (35)	( 400,475 )	( 374,273 )
Capitalized interest on property, plant, and equipment	6 (8) (35)	( 8,663 )	( 2,417 )
Disposal of property, plant and equipment	6 (8)	4,172	7,442
Acquisitions of intangible assets		( 340 )	( 443 )
Decrease in refundable deposits		4,810	29,420
Net Cash Outflows from Investing Activities		<u>( 398,496 )</u>	<u>( 444,928 )</u>
<b><u>Cash Flows from Financing Activities</u></b>			
Short-term loans - Proceeds for the current period	6 (36)	1,270,000	1,780,031
Short-term loans - Repayments for the current period	6 (36)	( 1,120,031 )	( 1,810,730 )
Long-term loans - Proceeds for the current period	6 (36)	239,800	-
Long-term loans - Repayments for the current period	6 (36)	( 9,616 )	( 9,489 )
Repayment of bonds payable	6 (17) (36)	( 46,200 )	-
Repayment of the principal portion of lease liabilities	6 (36)	( 12,872 )	( 4,163 )
Distribution of cash from capital surplus	6 (22)	-	( 44,118 )
Cash dividends paid	6 (23)	( 43,789 )	-
Other payables – related parties	7	1,800	-
Cash dividends distributed by subsidiaries to non-controlling interests		( 26,475 )	-
Cost of treasury shares repurchased	6 (21)	( 33,309 )	-
Changes in non-controlling interests		-	6,153
Net cash inflows from financing activities		<u>113,748</u>	<u>338,025</u>
Currency translation impact		<u>2,903</u>	<u>( 4,575 )</u>

Attached are the notes to the consolidated financial statements, which form an integral part of this consolidated financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited and Subsidiaries  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

	Note	(In Thousands of New Taiwan Dollars)	
		December 31, 2025	December 31, 2024
Net increase (decrease) in cash and cash equivalents		37,015	( 45,575 )
Cash and cash equivalents at beginning of year		277,458	323,033
Cash and cash equivalents at end of year		\$ 314,473	\$ 277,458

Attached are the notes to the consolidated financial statements, which form an integral part of this consolidated financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

## Independent Auditor's Report

(115) Cai-Sen-Bao-25004851

To the Board of Directors and Shareholders of OK Biotech Company Limited

### **Opinion**

We have audited the accompanying parent company only financial statements of OK Biotech Company Limited (the "Company"), which comprise the parent company only balance sheets as of December 31, 2025, and 2024, and the parent company only statements of comprehensive income, changes in equity, and cash flows for the years then ended. Additionally, the accompanying notes to the parent company only financial statements are included, providing material accounting policy information.

Based on the results of our audit and the audit reports of other auditors (please refer to the Other Matters paragraph), in our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2025, and 2024, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers..

### **Basis for Opinion**

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountants of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on our audit results and the audit reports of other auditors, we believe we have obtained sufficient and appropriate audit evidence to provide the basis for our audit opinion.

### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon. We do not provide a separate opinion on these matters.

Key audit matters for the Company's parent company only financial statements for the year ended December 31, 2025, are stated as follows:

## **Assessment of Impairment for Subsidiaries Accounted for Using Equity Method**

### Explanation of Matters

For details regarding the accounting policies of impairment assessments of non-financial assets, please refer to Notes 4 (17). For details on the impairment assessment of subsidiaries accounted for using equity method, please refer to Notes 6 (7) and 6 (8) of the parent company only financial statements. For a description of accounting estimates and assumptions, please refer to Note 5.

On December 31, 2025, the subsidiary, held by the Company under the equity method is Prodigy Diabetes Care, LLC, with an amount totaling NT\$449,010 thousand, where the recoverable amount of investments accounted for using the equity method is evaluated based on their fair value, which is determined by estimating the future cash flows generated by financial forecasts prepared by management, discounted at an appropriate discount rate, to assess whether there is any impairment. Given that this estimation involves various assumptions such as determining discount rates, expected growth rates, and future financial budgets, it is subject to subjective judgment and uncertainty, leading to significant impacts on the measurement of recoverable amounts. Therefore, we consider the impairment assessment of investments accounted for using the equity methods as one of the key audit matters.

### Audit Procedures Undertaken

Our auditors have executed the following audit procedures:

1. Reviewed the reasonableness of the valuation methods employed in the assessment reports of external experts.
2. Assessed the reasonableness of using revenue growth rates and gross profit margins and compared them with historical results.
3. Evaluated the parameters of discount rates used, including weighted average cost of capital, return on assets, and risk-free rates.

## **Sales Revenue Validity**

### Explanation of Matters

Regarding the accounting policy for revenue recognition, please refer to Note 4(29) of the parent company only financial statements for detailed explanations on revenue recognition. For details on revenue items, please refer to Note 6(22) of the parent company only financial statements.

The Company's sales are distributed among customers in Taiwan, Asia, the Americas, and Africa, among other countries. With transaction terms vary depending on market conditions and customer needs. Considering that sales revenue is a significant aspect of the Company's transactions, has a major impact on the financial statements, and requires substantial time and resources for verification, we have identified the validity of sales revenue as one of the key audit matters for the current audit.

### Audit Procedures Undertaken

Our audit procedures related to the sales revenue validity included the following, among others:

1. Evaluated the appropriateness of the revenue recognition accounting policy.
2. We assessed and tested the internal control system and actual process execution for sales transactions.
3. Conducted substantive tests of transactions for sales revenue transactions. These tests involved verification of documentation related to recognizing sales revenue, examination of transaction terms, performance obligations, and transaction prices to confirm the occurrence of transactions, and execution of accounts receivable collection procedures.

## **Other Matters: Reference to the Audit of Other Auditors**

The financial statements of certain subsidiaries and equity method investees included in the parent company only financial statements of the Company for the year 2025 and 2024 were audited by other auditors, and not by us. Accordingly, with respect to the amounts and disclosures relating to the financial statements and equity method investees, our opinion is based on the report(s) of the other auditors. As of December 31, 2025 and 2024, the investments in companies accounted for using the equity method Ending Balance to NT\$43,047 thousand and NT\$50,359 thousand, representing 1.19% and 1.44% of the total individual assets, respectively. For the years ended December 31, 2025 and 2024, the comprehensive losses recognized for the aforementioned companies amounted to NT\$(9,839) and NT\$7,787 thousand, representing (11.78%) and 7.96% of the comprehensive income, respectively.

## **Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements**

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including members of the Audit Committee) are responsible for overseeing the Company's financial reporting process.

## **Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements**

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements may arise due to fraud or error. A misstatement is considered material if it could reasonably be expected to influence the economic decisions of users taken based on the parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also performed the following procedures:

1. Identified and assessed the risks of material misstatement in the parent company only financial statements due to fraud or error; designed and performed appropriate responses to the assessed risks; and obtained sufficient and appropriate audit evidence to form the basis for the audit opinion. The risk of a material misstatement due to fraud was higher than that due to error, as fraud may involve collusion, forgery, deliberate omission, misrepresentation, or circumvention of internal controls.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluated the appropriateness of accounting policies used and the reasonableness of accounting

estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions were based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicated with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit.

We also provided those charged with governance with a statement that the personnel of our firm, subject to independence regulations, had complied with the independence requirements outlined in the Code of Ethics for Professional Accountants of the Republic of China, and communicated with them all relationships and other matters that may reasonably be thought to affect our independence, including related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2024 and are therefore the key audit matters. In the audit report, we disclosed these matters, unless the law prohibited the disclosure of certain matters or, in extremely rare circumstances, we decided not to communicate certain matters in the audit report because we reasonably expected that the negative consequences of such communication would outweigh the public interest that would be served.

PwC Taiwan

Chiang Tsai-Yen

CPA:

Jang Cheng-Han

Financial Supervisory Commission Approval

No. of Certification: Jin-Guan-Zheng-Shen-Zi No. 1060025097

Financial Supervisory Commission Approval

No. of Certification: Jin-Guan-Zheng-Shen-Zi No. 1130350413

March 10, 2026

OK Biotech Company Limited  
PARENT COMPANY ONLY BALANCE SHEETS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

Assets	Note	December 31, 2025		December 31, 2024		
		Amount	%	Amount	%	
<b>Current assets</b>						
1100	Cash and cash equivalents	6 (1)	\$ 287,642	8	\$ 230,119	7
1110	Financial assets at fair value through profit or loss - Current	6 (2)	12,586	-	13,042	-
1150	Net amount of notes receivable	6 (4)	95	-	39	-
1170	Net amount of accounts receivable	6 (4)	319,557	9	500,494	14
1180	Net amount of accounts receivable from related parties	6 (4) & 7	69,557	2	39,981	1
1200	Other receivables		4,370	-	10,755	-
1220	Income tax assets		16,937	1	16,946	-
130X	Inventories	6 (5)	354,948	10	402,140	12
1410	Prepayments	7	45,917	1	52,277	2
1470	Other current assets		1,440	-	800	-
11XX	<b>Total current assets</b>		<b>1,113,050</b>	<b>31</b>	<b>1,266,593</b>	<b>36</b>
<b>Non-current assets</b>						
1517	Financial assets at fair value through other comprehensive income - Non-current	6 (3)	12,701	-	11,369	-
1550	Investments accounted for using equity method	6 (7)(8)	493,441	14	535,772	15

OK Biotech Company Limited  
PARENT COMPANY ONLY BALANCE SHEETS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

1600	Property, plant and equipment	6 (9) & 8	1,917,322	53	1,584,696	46
1780	Intangible assets		111	-	172	-
1840	Deferred tax assets and liabilities	6 (29)	72,001	2	62,340	2
1900	Other non-current assets	6 (6) & 7	14,629	-	31,453	1
15XX	<b>Total non-current assets</b>		<u>2,510,205</u>	<u>69</u>	<u>2,225,802</u>	<u>64</u>
1XXX	<b>Total assets</b>		<u>\$ 3,623,255</u>	<u>100</u>	<u>\$ 3,492,395</u>	<u>100</u>

(Next page)

OK Biotech Company Limited  
PARENT COMPANY ONLY BALANCE SHEETS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

Liabilities and Equities	Note	December 31, 2025		December 31, 2024		
		Amount	%	Amount	%	
<b>Current liabilities</b>						
2100	Short-term loans	6 (10) & 8	\$ 290,000	8	\$ 300,000	9
2120	Financial liabilities at fair value through profit or loss - Current	6 (11)	-	-	653	-
2130	Contracts liabilities - Current	6 (22)	10,955	-	8,217	-
2150	Notes payable	6 (31)	20,832	1	59,383	-
2170	Accounts payable	6 (12)	57,652	2	126,893	4
2180	Accounts payable from related parties	7	51,493	1	58,922	2
2200	Other payables	6 (13)	56,378	2	52,081	1
2220	Other payables from related parties	7	1,168	-	2,042	-
2230	Income tax liabilities		2,239	-	11,872	-
2320	Long-term loans due within one year or one operating cycle	6 (14) (15) & 8	10,185	-	55,462	2
2399	Other current liabilities - Other		640	-	693	-
21XX	<b>Total current liabilities</b>		<u>501,542</u>	<u>14</u>	<u>676,218</u>	<u>20</u>
<b>Non-current liabilities</b>						

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT COMPANY ONLY BALANCE SHEETS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

2540	Long-term loans	6 (15) & 8	606,424	17	321,996	9
2570	Deferred tax liabilities	6 (29)	2,043	-	2,084	-
2600	Other non-current liabilities		24	-	24	-
25XX	<b>Total non-current liabilities</b>		<u>608,531</u>	<u>17</u>	<u>324,104</u>	<u>9</u>
2XXX	<b>Total liabilities</b>		<u>1,110,073</u>	<u>31</u>	<u>1,000,322</u>	<u>29</u>
	Capital share	6(18)				
3110	Capital Share - Common Share		1,448,142	40	1,470,592	42
	Capital Surplus	6 (19)				
3200	Capital Surplus		885,197	24	890,594	26
	Retained Earnings	6 (20)				
3310	Legal Capital Reserve		147,425	4	138,478	4
3320	Special Capital Reserve		19,581	-	19,580	-
3350	Undistributed Earnings		96,695	3	89,471	2
	Other Equity	6 (21)				
3400	Other Equity		( 83,858)	( 2)	( 116,642)	( 3)
3XXX	<b>Total equity</b>		<u>2,513,182</u>	<u>69</u>	<u>2,492,073</u>	<u>71</u>
	Significant contingent liabilities and	9				

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT COMPANY ONLY BALANCE SHEETS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

	unrecognized commitments					
	Significant subsequent events	11				
3X2X	Total liabilities and equities		\$	3,623,255	100	\$
				3,492,395	100	

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT ONLY STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE YEARS ENDED DECEMBER 31, 2024, AND 2023

(In Thousands of New Taiwan Dollars)  
(Except Earnings per Share in NT\$)

Item	Note	2025		2024	
		Amount	%	Amount	%
4000 Operating revenue	6 (22) & 7	\$ 1,241,285	100	\$ 1,593,512	100
5000 Operating cost	6 (5) (27) (28) & 7	( 1,019,280)	( 82)	( 1,393,664)	( 87)
5900 Gross profit (loss) from operations		<u>223,005</u>	<u>18</u>	<u>199,848</u>	<u>13</u>
5910 Unrealized profit (loss) from sales	6 (7)	( 15,838)	( 1)	( 4,366)	-
5920 Realized profit (loss) from sales	6 (7)	<u>4,366</u>	<u>-</u>	<u>6,293</u>	<u>-</u>
5950 Net gross profit (loss) from operations		<u>211,533</u>	<u>17</u>	<u>201,775</u>	<u>13</u>
Operating expenses	6 (27) (28)				
6100 Marketing		( 37,006)	( 3)	( 59,119)	( 4)
6200 General and administrative		( 57,927)	( 5)	( 68,395)	( 4)
6300 Research and development		( 44,891)	( 3)	( 51,640)	( 3)
6450 Gain (loss) on expected credit losses	12 (2)	( 11,244)	( 1)	<u>10,840</u>	-
6000 Total operating expenses		( 151,068)	( 12)	( 168,314)	( 11)
6900 Net operating income		<u>60,465</u>	<u>5</u>	<u>33,461</u>	<u>2</u>
Non-operating income and expenses					
7100 Interest income	6 (23) & 7	3,258	1	5,698	-
7010 Other income	6 (24) & 7	12,670	1	16,972	1

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT ONLY STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE YEARS ENDED DECEMBER 31, 2024, AND 2023

(In Thousands of New Taiwan Dollars)  
(Except Earnings per Share in NT\$)

7020	Other gains and losses	6 (25)	(	14,667)	(	1)	41,852	3
7050	Finance costs	6 (26)	(	10,322)	(	1)	5,919)	-
7070	Share of profit (loss) of subsidiaries, associates and joint ventures accounted for using equity method	6 (7)		40,311		3	23,362	1
7000	Total non-operating income and expenses			<u>31,250</u>		<u>3</u>	<u>81,965</u>	<u>5</u>
7900	<b>Net profit before tax</b>			91,715		8	115,426	7
7950	Income tax expenses	6 (29)	(	9,266)	(	1)	21,451)	(
8200	<b>Net profit</b>			<u>\$ 82,449</u>		<u>7</u>	<u>\$ 93,975</u>	<u>6</u>

**Other comprehensive income (loss), net of income tax**

**Items that will not be reclassified subsequently to profit or loss:**

8316	Unrealized profits (losses) on equity investments at fair value through other comprehensive income	6 (3) (21)		\$ 1,332		-	\$ 250	-
8310	Total items that will not be reclassified subsequently to profit or loss			<u>1,332</u>		<u>-</u>	<u>250</u>	<u>-</u>

**Items that may be reclassified subsequently to profit or loss**

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT ONLY STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE YEARS ENDED DECEMBER 31, 2024, AND 2023

(In Thousands of New Taiwan Dollars)  
(Except Earnings per Share in NT\$)

8361	Exchange differences arising on translation of foreign operating entity	6 (7) (21)	(	330)	-	4,573	-
8399	Income tax relating to items that may be reclassified	6 (21) (29)		66	-	( 915)	-
8360	Items that may be reclassified subsequently to profit or loss		(	264)	-	3,658	-
8300	<b>Other comprehensive income (loss), net of income tax</b>		\$	1,068	-	\$ 3,908	-
8500	<b>Total comprehensive income</b>		\$	83,517	7	\$ 97,883	6
	Basic earnings per share	6 (30)					
9750	Net profit		\$	0.58		\$ 0.66	
	Diluted earnings per share	6 (30)					
9850	Net profit		\$	0.57		\$ 0.64	

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

Note	Capital Surplus				Retained Earnings			(In Thousands of New Taiwan Dollars)			
	Capital Share - Common Share	Capital Surplus - Premium on Issuance	Capital Surplus - Others	Capital Surplus - Restricted Stock	Legal Capital Reserve	Special Capital Reserve	Undistributed Earnings	Other Equity	Treasury Stock	Total Equity	
<u>2024</u>											
	Balance, January 1, 2024	\$ 1,457,698	\$ 858,544	\$ 5,942	\$ 57,800	\$ 138,466	\$ 19,464	\$ 128	(\$ 140,193)	\$ -	\$ 2,397,849
	Net profit	-	-	-	-	-	-	93,975	-	-	93,975
	Other comprehensive income	6 (21)	-	-	-	-	-	-	3,908	-	3,908
	Total comprehensive income	-	-	-	-	-	-	93,975	3,908	-	97,883
	Appropriation and distribution of retained earnings for the years ended 2023	6 (20)	-	-	-	-	-	-	-	-	-
	Recognition of legal capital reserve	-	-	-	-	12	-	( 12)	-	-	-
	Recognition of special capital reserve	-	-	-	-	-	116	( 116)	-	-	-
	Cash distribution from capital surplus	6 (19)	( 44,118)	-	-	-	-	-	-	-	( 44,118)
	Cancellation of restricted stock awards	6 (17)(18)	( 610)	-	610	-	-	-	-	-	-
	Transfer of corporate bonds	6 (14)(18)	13,504	12,138	( 322)	-	-	-	-	-	25,320
	Cost of restricted stock awards (RSA)	6 (17)(21)	-	-	-	-	-	-	19,643	-	19,643
	Vested restricted stock awards (RSA)	6 (17)(21)	-	58	( 58)	-	-	-	-	-	-
	Non-proportional subscription of newly issued shares by subsidiary	6 (7)	-	-	-	-	-	( 4,504)	-	-	( 4,504)
	Balance, December 31, 2023	\$ 1,470,592	\$ 826,622	\$ 5,620	\$ 58,352	\$ 138,478	\$ 19,580	\$ 89,471	(\$ 116,642)	\$ -	\$ 2,492,073
<u>2025</u>											
	Balance, January 1, 2025	\$ 1,470,592	\$ 826,622	\$ 5,620	\$ 58,352	\$ 138,478	\$ 19,580	\$ 89,471	(\$ 116,642)	\$ -	\$ 2,492,073
	Net profit	-	-	-	-	-	-	82,449	-	-	82,449
	Other comprehensive income	6 (21)	-	-	-	-	-	-	1,068	-	1,068
	Total comprehensive income	-	-	-	-	-	-	82,449	1,068	-	83,517
	Appropriation and distribution of retained earnings for the year ended 2024	6 (20)	-	-	-	-	-	-	-	-	-
	Cash Dividend	-	-	-	-	-	-	( 43,789)	-	-	( 43,789)
	Recognition of legal capital reserve	-	-	-	-	8,947	-	( 8,947)	-	-	-
	Recognition of special capital reserve	-	-	-	-	-	1	( 1)	-	-	-
	Issuance of restricted stock awards	6 (17)	1,750	-	963	-	-	-	( 2,713)	-	-
	Cancellation of restricted stock awards	6 (17)	( 4,200)	-	4,200	-	-	-	-	-	-
	Cost of restricted stock awards	6 (18)(21)	-	-	-	-	-	-	14,690	-	14,690
	Disposal of financial assets measured at FVOCI	6 (3)(21)	-	-	-	-	-	( 19,739)	19,739	-	-
	Repurchase of Treasury Shares	6 (18)	-	-	-	-	-	-	-	( 33,309)	( 33,309)
	Cancellation of Treasury Shares	6 (18)	( 20,000)	( 10,500)	( 60)	-	-	( 2,749)	-	33,309	-
	Balance, December 31, 2025	\$ 1,448,142	\$ 816,122	\$ 9,760	\$ 59,315	\$ 147,425	\$ 19,581	\$ 96,695	(\$ 83,858)	\$ -	\$ 2,513,182

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

OK Biotech Company Limited  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

	Note	December 31, 2025		December 31, 2024
<u>Statement of Cash Flows from Operating Activities</u>				
Pre-tax net income for the period		\$ 91,715		\$ 115,426
Adjustments for:				
Income and expense				
Depreciation expense	6 (9) (27)	64,376		61,235
Amortization expense	6 (27)	61		1,798
Losses (gains) on expected credit losses	12 (2)	11,244	(	10,840 )
Net (profit) loss from financial assets and liabilities at fair value through profit or loss	6 (2) (11) (25)	197	(	2,962 )
Interest expense	6 (26)	10,322		5,919
Interest income	6 (23)	3,258	(	5,698 )
Share-based cost for compensation	6 (17) (28)	14,690		19,643
Share of profit (loss) of associates and joint ventures accounted for using equity method	6 (7)	40,311	(	23,362 )
Profit (loss) on disposal of investments	6 (7) (25)	1,214	(	4,003 )
Profits on disposal of property, plant, and equipment	6 (25)	3,314	(	2,314 )
Unrealized (Realized) gains on transactions with associated companies	6 (7)	11,472	(	1,927 )
Changes in operating assets/liabilities				
Net changes in operating assets				
Net changes in financial assets at fair value through profit or loss		-		26,276
Notes receivable		56	(	517 )
Notes receivable from related parties		-		208
Accounts receivable		169,693	(	180,305 )
Accounts receivable from related parties		29,576	(	78,113 )
Other receivables		6,385	(	647 )
Inventories		47,192	(	61,969 )
Prepayments		6,360		43,950
Other current assets		640	(	3,657 )
	(Next page)			

OK Biotech Company Limited  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

	Note	December 31, 2025	December 31, 2024
Net changes in operating liabilities			
Contracts liabilities		2,738	( 55,265 )
Notes payable		( 708 )	1,037
Accounts payable		( 69,241 )	14,424
Accounts payable from related parties		( 7,429 )	( 11,429 )
Other payables		( 8,690 )	14,041
Other payables from related parties		( 874 )	1,666
Other current liabilities		( 53 )	263
Cash inflow generated form operation		270,687	41,382
Interest received		3,258	5,698
Dividends received	6 (7)	73,368	17,281
Interest paid		( 9,524 )	( 4,881 )
Income taxes refunded		-	17,173
Income taxes paid		( 28,526 )	( 8,185 )
Net cash inflow (outflow) generated from operation		309,263	( 68,468 )
	Note	December 31, 2025	December 31, 2024
<u>Cash Flows from Investing Activities</u>	Note	December 31, 2025	December 31, 2024
Other receivables from related parties	7	\$ -	\$ 4,500
Disposal of financial assets measured at amortized cost		-	30,000
Acquisition of financial assets at fair value through other comprehensive income	6 (3) & 12 (2)	-	( 1,243 )
Acquisition of subsidiaries	6 (7)	-	( 145,101 )
Disposal of equity method investments	6 (7)	2,000	3,500
Acquisitions of property, plant and equipment	6 (31)	( 402,397 )	( 373,208 )
Capitalized interest on property, plant, and equipment	6 (9) (31)	( 8,668 )	( 2,417 )
Disposal of property, plant and equipment	6 (9)	-	7,442
Acquisitions of intangible assets		-	( 182 )
Decrease in refundable deposits		6,026	29,420
Net Cash Outflows from Investing Activities		( 403,034 )	( 447,289 )

(Next page)

OK Biotech Company Limited  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

(In Thousands of New Taiwan Dollars)

	Note	December 31, 2025	December 31, 2024
	Note	December 31, 2025	December 31, 2024
<u>Cash Flows from Financing Activities</u>			
Short-term loans - Proceeds for the current period	6 (32)	\$ 3,350,000	\$ 1,270,000
Short-term loans - Repayments for the current period	6 (32)	( 3,360,000 )	( 1,120,031 )
Long-term loans - Proceeds for the current period	6 (15) (32)	294,400	( 239,800 )
Long-term loans - Repayments for the current period	6 (15) (32)	( 9,807 )	( 9,616 )
Repayment of Bonds Payable	6 (14) (32)	( 46,200 )	-
Cash paid from capital surplus	6 (19) (20)	-	( 44,118 )
Cash dividends paid	6 (20)	( 43,789 )	-
Capital Increase for subsidiary	6 (7)	-	( 9,846 )
Cost of Treasury Share Repurchase	6 (18)	( 33,309 )	-
Net Cash Inflows from Financing Activities		( 151,295 )	( 326,189 )
Net increase (decrease) in cash and cash equivalents		57,524	( 52,632 )
Cash and cash equivalents at beginning of year		230,119	282,751
Cash and cash equivalents at end of year		\$ 287,643	\$ 230,119

Attached are the notes to the parent company only financial statements, which form an integral part of this parent company only financial report. Please refer to them accordingly.

Chairman: LAI, CHIA-DE

Manager: LAI, CHIA-DE

Accountant Supervisor: HOU, CHI-CHENG

## OK Biotech Company Limited

### Execution status of share repurchase (completed)

Number of share repurchase rounds	First Tranche	Second Tranche
Purpose of the share repurchase	To safeguard the Company's credit and protect shareholders' interests	To safeguard the Company's credit and protect shareholders' interests
Repurchase period	2025/04/11~2025/06/09	2025/08/22~2025/10/21
Repurchase price range (NT\$)	10.00~30.00	11.30~23.60
Types and number of repurchased shares (shares)	Common shares /1,000,000 Shares	Common shares /1,000,000 Shares
Amount of repurchased shares (NT\$)	17,676,106	15,632,711
Ratio of repurchased shares to planned quantity (%)	100	100
Number of shares cancelled (shares)	1,000,000	1,000,000
Accumulated number of shares held in the Company (shares)	1,000,000	1,000,000
Ratio of accumulated shareholding in the Company to total issued shares (%)	0.68	0.68
This item was not completed.	NA	NA

**OK Biotech Company Limited**  
**2025 Earning Distribution Table**

(In NT\$)

1. Undistributed Earnings at the Beginning of the Period	\$	36,408,124
Plus: Net Profit after Tax for the Period		82,449,195
Less: Disposal of financial assets measured at FVOCI		(19,738,600)
Less: Cancellation of treasury shares		(2,749,178)
Less: Special Capital Reserve		0
Less: 10% of the Legal Capital Reserve		(5,996,142)
2. Earnings Available for Distribution for the Period		90,373,399
3. Distribution Item		
Cash Dividends to Shareholders (cash dividend of NT\$0.3 per share; see Note 3.)		43,444,249
Stock Dividends to Shareholders		0
Subtotal		43,444,249
4. Undistributed Earnings at the End of the Period	\$	46,929,150

## Note:

1. The Company adopts a distribution policy prioritizing the distribution of profits for the year ended December 31, 2025. Any shortfall will be distributed according to the year in which the profits were generated, following the first in, first out (FIFO) principle.
2. As other equity changes for the current period are positive, no special reserve for earnings appropriation is proposed.
3. For the 2025 earnings distribution of cash dividends, the total distribution amount is tentatively calculated based on the Ministry of Economic Affairs' registered paid-in capital of 144,814,164 shares as of March 2, 2026. Maintaining the cash dividend at NT\$0.3 per share, if prior to the ex-dividend date any adjustments are required by the competent authority, or if changes in the Company's capital affect the number of outstanding shares and thereby alter the total cash dividend amount, the Chairman is authorized to handle such matters with full discretion.
4. This resolution was approved by the Board of Directors on March 10, 2026, and will be reported to the Shareholders' Meeting.

**Chairman****Manager****Accountant Supervisor**

**OK Biotech Company Limited**  
**Shareholdings of All Directors**

(in Shares)

<b>Title</b>	<b>Item</b>	<b>Actual Shareholding</b>
Chairman	Shang Shun Development Co., Ltd. / Representative: Lai, Chia-De	2,061,044
Vice Chairman	Liu, Yu-Tzu	855,195
Director	He-Qun Investment Co., Ltd. / Representative Chen, Chin-Piao	6,852,373
Director	Ting-Fa Investment Co., Ltd. / Representative Wang, Zhen-Gang	6,389,720
Director	Bei Xi Co., Ltd. / Representative Xu, Jin-Yuan	1,958,000
Director	Lan, Shi-Wan	818,000
Director	Hou, Qi-Zheng	19,617
Independent Director	Chen, Ku-Chuan	0
Independent Director	Lin, Shih-Yi	0
Independent Director	Ho, Li-Fen	53,663
Independent Director	Lu, Ching-Chun	0
Total Shareholdings of All Directors (Shares)		19,007,612
Accounting for Total Issued Share (%)		13.13%
Shares Shall Be Held by All Directors		8,688,850

Note:

1. Based on the total issued shares of 144,814,164 as of the shareholders' meeting record date on April 4, 2026 (including 120,000 restricted employee shares that have been repurchased and cancelled but not yet registered for capital change), the Company's paid-in capital amounts to NT\$1,448,141,640. In accordance with the Regulations Governing Shareholding Ratios of Directors and Supervisors of Public Companies and relevant audit rules, since the Company has elected independent directors, the required shareholding ratio for all directors is reduced to 80%. Accordingly, the minimum number of shares to be held collectively by all directors is 8,688,850 shares.
2. As of the adjournment date of the Annual Shareholders' Meeting on April 4, 2026, the total actual shares held by all directors of the Company amounted to 19,007,612 shares, representing 13.13% of the total shares of the Company.

**OK Biotech Company Limited**  
**Articles of Incorporation**

**Chapter 1      General Provisions**

- Article 1**    **The Corporation shall be incorporated, as a company limited by shares, under the Company Act of the Republic of China, and its name shall be OK Biotech Company Limited in the Chinese language, and OK Biotech Company Limited in the English language.**
- Article 2**    **The scope of business of the Corporation shall be as follows:**  
**CC01080** Electronic Component Manufacturing  
 F119010 Wholesale of Electronic Material  
 F219010 Retail of Electronic Materials  
 F401010 International Trade  
 I501010 Product Designing  
 CF01011 Medical Materials and Equipment Manufacturing  
 F108031 Wholesale of Medical Devices  
 F208231 Retail Sale of Medical Devices.  
 F108011 Wholesale of Chinese Medicines  
 F208011 Retail Sale of Traditional Chinese Medicine  
 F108021 Wholesale of Drugs and Medicines  
 F208021 Retail Sale of Drugs and Medicines  
 CC01101 Restrained Telecom Radio Frequency Equipments and Materials Manufacturing  
 F401021 Restrained Telecom Radio Frequency Equipment and Materials Import.  
 ZZ99999 All business items that are not prohibited or restricted by law, except those that are subject to special approval.
- Article 2-1** **The Company may provide external guarantees due to business needs.**
- Article 3**    **The headquarter of the Company is located in Hsinchu City. When necessary, it can establish branches, offices or factories at home or abroad basic upon the resolution of the Board of Directors.**
- Article 4**    **The Company's announcement method shall be handled in accordance with Article 28 of the Company Act of Republic of China.**

## **Chapter 2      Shares**

**Article 5    The total capital amount of the Company is NT\$3 billion, divided into 300 million shares with a par value of NT\$ 10 per share. The Board of Directors is authorized to issue the shares in stages.**

**Within the aforementioned total capital amount, NT\$300 million is reserved for issuance of stock option certificates, totaling 30 million shares with a par value of NT\$10 per share, to be issued by the Board of Directors in stages as deemed necessary for business purposes**

**Treasury stocks acquired by the Company may be transferred to employees of subsidiaries who meet certain criteria.**

**Employee stock warrants may be issued to employees of subsidiaries who meet certain criteria.**

**Employees of subsidiaries who meet certain criteria may subscribe to shares when the Company issues new shares.**

**The objects of restricted stock awards to employees may include employees of subsidiaries who meet certain criteria.**

**Article 6    The stock certificate of the Company shall be in registered form, signed and numbered by the director representing the Company, and shall contain the items listed in Article 162 of the Company Act, and shall be issued after being legally certified.**

**After the Company makes a public offering of shares, when issuing new shares, it may consolidate and print the share certificates for the total number of shares issued, or may be exempted from printing share certificates, but shall contact the centralized securities depository institution for safekeeping or registration.**

**Article 7    The Company's stock transfer, establishment, pledge, loss, inheritance, gift, change of seal or report of loss, change of address and other related stock affairs operations shall be handled in accordance with the provisions of the Company Act and relevant laws and regulations. After the Company's public offering of stocks, Stock affairs operations are also handled in accordance with the "Regulations Governing the Administration of Shareholder Services of Public Companies."**

**Article 8** Changes to the shareholder register shall be stopped within 30 days before the regular Shareholders' Meeting, within 15 days before the extraordinary Shareholders' Meeting, or within 5 days before the company decides to distribute dividends, bonuses or other benefits. After the public offering of shares by the company, the changes recorded in the shareholders' register shall cease within 60 days before the regular Shareholders' Meeting and within 30 days before the Special Shareholders' Meeting.

### **Chapter 3 Shareholder's Meeting**

**Article 9** There are two types of shareholder meetings respectively as Annual Shareholder's Meetings and Special Shareholders' Meetings. Annual Shareholder's Meetings are held once a year, and are convened by the Board of Directors within six months after the end of each fiscal year. The Extraordinary Shareholders' Meetings shall be convened in accordance with law when necessary.

**Article 9-1** When convening a Shareholder's Meeting, electronic means shall be listed as one of the channels for shareholders to exercise their voting rights, and shareholders may exercise their voting rights in written or electronic means; when they exercise their voting rights in written or electronic means, the exercise method shall be specified in Shareholders' Meeting convened notice.

**Article 9-2** Method and location of convening the Shareholders' Meeting:

- 1.** For physical Shareholders' Meetings convened by the company, the venue of the Shareholders' Meeting shall be specified.
- 2.** For physical Shareholders' Meetings with video assistance (hereinafter referred to as video-assisted Shareholders' Meetings), in addition to specifying the venue of the physical Shareholders' Meeting, the video conferencing platform used for the video-assisted meeting shall also be specified.
- 3.** For Shareholders' Meetings held solely via video conferencing without a physical meeting (hereinafter referred to as virtual Shareholders' Meetings), the video conferencing platform used by

**the Company shall be specified.**

**Article 10** When a shareholder is unable to attend the Shareholders' Meeting for any reason, he or she shall issue a power of attorney issued by the company specifying the scope of authorization, sign and seal the proxy to entrust an agent to attend.

**Article 11** The Shareholders' Meeting convened by the Board of Directors shall be presided over by the chairman as stipulated in Article 208, Paragraph 3 of the Company Act. If convened by any person other than the board of directors, the chairman shall be appointed by that person. If there are two or more conveners, they shall mutually elect one to serve as chairman.

When the Company's shareholder is only one legal entity shareholder, the functions and powers of the Company's Shareholders' Meeting are exercised by the Board of Directors, and the provisions of the articles of incorporation regarding the Shareholders' Meeting do not apply.

**Article 12** Unless otherwise stipulated by relevant laws and regulations, the shareholders of the Company shall have one voting right per share.

**Article 13** Unless otherwise stipulated by the Company Act, the resolutions of the Shareholders' Meeting shall be attended by shareholders representing more than half of the total number of issued shares, and shall be carried out with the consent of more than half of the voting rights of the present shareholders.

**Article 13-1** After the company's public offering of stocks, if there is a plan to cancel the public offering, in addition to the approval of the Board of Directors, it must be submitted to the Shareholders' Meeting for approval, and this provision will not be changed during the listing period.

**Article 14** The resolutions of the shareholders' meeting shall be recorded in minutes, signed or sealed by the chairman, and distributed to all shareholders within 20 days after the meeting. Regarding the distribution of the meeting minutes may be done by announcement.

The minutes of the meeting shall record the year, month, day, venue, name of the chairman, and resolution method of the meeting, and shall record the essentials and results of the proceedings. Handled in

accordance with Article 183 of the Company Act.

#### **Chapter 4        Directors**

**Article 15**    The Company has seven to fifteen directors. The election of directors is handled in accordance with relevant laws and regulations. The term of office is three years. When the term of office of directors expires and there is no time for re-election, the executive duties shall be extended until the re-elected director takes office; when the vacancy of directors reaches one-third, the Board of Directors shall hold an extraordinary meeting of shareholders within 60 days for by-election, and the limit shall be to make up for the original term of office.

After the Company's public offering of shares, in accordance with the provisions of the Securities and Exchange Act, the Company shall have at least two independent directors and not less than one-fifth of the number of directors in the above-mentioned number of directors. All directors of the Company adopt a candidate nomination system, and shareholders are elected from a list of director candidates. The professional qualifications, shareholding, part-time job restrictions, nomination and election methods, and other compliance matters of independent directors shall be handled in accordance with the relevant regulations of the security's competent authority.

**Article 15-1** The Company shall set up an Audit Committee in accordance with Article 14-4 of the Securities and Exchange Act. The audit committee shall be composed of all independent directors, the number of which shall not be less than three, and one of them shall be the convener. The Audit Committee or the members of the Audit Committee are responsible for the execution of the duties and powers of the supervisors stipulated in the Company Act, the Securities and Exchange Act, and other statutes.

**Article 16**    The Board of Directors shall be organized by directors, and more than two-thirds of the directors shall be present, and more than half of the directors' present shall agree to elect a Chairman from each other; the Company may elect a Vice Chairman from each other in the same way. The Chairman represents the Company externally and executes all the Company's affairs in accordance with the laws, articles of incorporation, resolutions of the Shareholders' Meeting and the Board

**of Directors.**

**Article 17** The Company's business policy and other important matters are resolved by the Board of Directors. Except for the first meeting of the Board of Directors in each session in accordance with Article 203 of the Company Act, the rest are convened by the Chairman and serve as the Chairman. When the Chairman of the Board of Directors asks for leave or is unable to exercise his powers for some reason, his agency shall be handled in accordance with the provisions of Article 208 of the Company Act.

**Article 18** The remuneration of all directors shall be paid at the authorized board meeting according to the normal level of the industry every year regardless of operating profit or loss.

The Company may purchase liability insurance for directors who are legally liable for compensation in respect of the scope of business performed during their term of office.

**Article 19** Deletion.

**Article 20** Deletion.

**Article 21** Unless otherwise stipulated by the Company Act, resolutions of the Board of Directors must be attended by more than half of the directors, and must be made with the consent of more than half of the directors' present. The scope of authorization is to entrust other directors to attend the Board of Directors on behalf of others, but only one person is entrusted by one person.

If the Board of Directors holds a video conference, the directors who participate in the meeting through video conference shall be deemed to have attended the meeting in person.

When the board of directors convenes, it shall specify the reasons and notify all directors seven days in advance; however, in case of emergency, it may be convened at any time, and the written notification may be replaced by fax or e-mail.

**Article 22** The proceedings of the Board of Directors shall be recorded in minutes, signed or sealed by the Chairman, and distributed to all directors within 20 days after the meeting. The minutes shall record the year, month, day, venue, and Chairman of the meeting. The preservation

period of names, resolution methods, essentials of the proceedings and their results, minutes of meetings, signature books of attending directors, and power of attorney for proxies shall be handled in accordance with Article 183 of the Company Act.

**Article 23 Deletion.**

## **Chapter 5 Managers**

**Article 24** The company may have a manager whose appointment, dismissal and remuneration shall be handled in accordance with Article 29 of the Company Act.

## **Chapter 6 Accountings**

**Article 25** The Company shall, at the end of each fiscal year, prepare by the Board of Directors:

**(A.) Business reports; (B.) Financial statement; (C.) Proposals on profit distribution or loss compensation; and other forms are submitted to the Annual Shareholders' Meeting in accordance with the law and requested for recognition.**

**Article 25-1** The Company shall distribute employee compensation based on 10% to 15% of the current year's profit status, and shall distribute director's remuneration at no higher than 2% of the current year's profit status. However, when the company has accumulated losses, they shall be compensated.

The Company's allocation of compensation to frontline employees shall not be less than 35% of the total compensation allocated to the employees specified in the first paragraph.

Employee compensation may be paid in stock or cash, and the recipients of the stock or cash may include employees of subsidiaries who meet certain conditions. The profit status of the current year referred to in the first paragraph refers to the current year's pre-tax profit before deducting the distribution of employee compensation and director's remuneration.

The distribution of employee compensation and director's remuneration shall be made by the Board of Directors with the resolution of more than two-thirds of the directors' present and the approval of more than half of the directors present, and report to the Shareholders' Meeting.

- Article 26** The Company's annual net profit is distributed in the following order:
1. Payment of taxes and donations.
  2. Offset of losses from previous years.
  3. Allocation of 10% as legal capital reserve.
  4. Other special surplus reserves are recognized or reversed in accordance with statutory regulations.
  5. The balance of shareholder bonuses or dividends after withdrawals in accordance with Subparagraphs 1 to 4 shall be determined by the Board of Directors and resolved by the Shareholders' Meeting

**Article 26-1** The Company's dividend policy is based on consideration of the Company's investment capital needs, financial balance, etc., and the Board of Directors will draft a profit distribution plan, which will be handled after the resolution of the Shareholders' Meeting.

The Company, considering a balanced and stable dividend policy, ensures that cash dividends distributed are not less than 10%

**Article 26-2** The Company authorizes the Board of Directors to distribute all the dividends and bonuses that should be distributed in accordance with the dividend policy of Article 26-1 of the Company's articles of incorporation with the attendance of more than two-thirds of the directors and the resolution of more than half of the directors present. Or part of it is done in the form of cash distribution and reported to the Shareholders' Meeting, and the provisions of the articles of incorporation related to the resolutions of the Shareholders' Meeting are not applicable.

**Article 26-3** The Company authorizes the Board of Directors, with the attendance of two-thirds or more of the directors and the approval of a majority of the directors present, to distribute all or part of the capital surplus or legal capital surplus in the form of cash and report it to the shareholders' meeting.

## **Chapter 7      Supplementary Provisions**

- Article 27** Due to the business requirements, the Company may reinvest at home and abroad upon resolution of the Board of Directors. The total investment is not subject to the restriction that reinvestment shall not exceed 40% of the paid-in capital in Article 13 of the Company Act.
- Article 28** In regard to all matters not provided for in these Articles of Incorporation, the Company Act of the Republic of China shall govern.
- Article 29** These Articles of Incorporation were enacted on September 23, 2004.  
The first amendment was made on January 22, 2006.  
The second amendment was made on June 6, 2006.  
The third amendment was made on November 22, 2006.  
The fourth amendment was made on October 26, 2007.  
The fifth amendment was made on October 1, 2008.  
The sixth amendment was made on November 13, 2008.  
The seventh amendment was made on May 7, 2009.  
The eighth amendment was made on December 14, 2009.  
The ninth amendment was made on May 14, 2010.  
The tenth amendment was made on April 21, 2011.  
The eleventh amendment was made on May 3, 2012.  
The twelfth amendment was made on March 15, 2013.  
The thirteenth amendment was made on May 27, 2014.  
The fourteenth amendment was made on June 8, 2015.  
The fifteenth amendment was made on August 25, 2015.  
The sixteenth amendment was made on May 24, 2017.  
The seventeenth amendment was made on May 30, 2018.  
The eighteenth amendment was made on May 30, 2019.  
The nineteenth amendment was made on May 28, 2020.  
The twentieth amendment was made on June 12, 2023.  
The twenty-first amendment was made on May 29, 2024.  
The twenty-second amendment was made on June 3, 2025.

**OK Biotech Company Limited**

**Chairman: Lai, Chia-De**

**OK Biotech Company Limited**  
**Rules of Procedure for Shareholders' Meetings**

- Article 1 Unless otherwise stipulated by laws or the Company's articles of association, the Shareholders' Meeting of the Company shall be transacted in accordance with the Rule and Procedures of Shareholders' Meeting (the "Rules") .
- Article 2 The Company shall provide a sign-in book for shareholders to sign in, or shareholders attending may submit an attendance card in lieu of signing in. The number of shares represented by shareholders attending the Meeting shall be calculated based on the attendance register or the submitted attendance cards. If the Company adopts the system that shareholders can exercise their voting rights in written or electronic means, the number of shares present shall be added to the number of shares that exercise their voting rights in written or electronic means in accordance with provision of regulations.
- Article 2-1 The Company shall specify the meeting time and location f in the notification for accepting shareholder, as well as other matters to be noted.
- The time for acceptance of shareholder registration in the preceding paragraph shall be transacted at least 30 minutes before the start of the meeting; the registration office shall be clearly marked, and the competent and qualified personnel shall be assigned in the process.
- Shareholders themselves or proxies entrusted by shareholders (hereinafter referred to as "shareholders") shall present their attendance certificates, attendance cards, or other attendance certificates to attend the Shareholders' Meeting; the solicitor of the power of attorney solicitation shall bring his identity documents for verification.
- Article 3 Attendance and voting at the Shareholders' Meeting shall be calculated on basis of shares.
- Article 4 The Meeting shall be held at the head office of the Company or at any other appropriate place that is convenient for the shareholders to attend. The time to start the Meeting shall not be earlier than 9:00 a.m. or later than 3:00 p.m.
- Article 5 The Chairman of the Shareholders' Meeting, when convened by the Board of Directors, shall be chaired by the Chairman of the Board of Directors. In event that the Chairman is unable to fulfill this duty due to leave or other reasons, the Vice Chairman shall act as the proxy. If there is no Vice Chairman available or if they are also absent, the Chairman of the Board shall appoint one Director to act as the proxy. If the Chairman fails to appoint a proxy, the Directors shall collectively nominate a proxy. The chairman referred to in the preceding paragraph shall be represented by a Vice Chairman or a director who has served for more than six months and who understands the Company's financial and business conditions. The same applies if the chairman is the representative of the corporate director. If the Meeting is convened by any other person entitled to convene the Meeting, such person shall be the chairman to preside at the Meeting. When the Shareholders' Meeting is in session, if the chairman violates the rules of proceedings and announces the dismissal of the Meeting, more than half of the voting rights of the shareholders present may elect a person to serve as the chairman and continue the meeting.

For the convening of an Annual Shareholders' Meeting, a manual of procedures shall be compiled and notified to all shareholders in accordance with the provisions of the articles of association.

Shareholders who hold more than 1% of the total number of issued shares may submit proposals for Annual Shareholders' Meeting to the Company, limited to one proposal per shareholder; any proposals exceeding this limit will not be included in the agenda. The provisions of the proposal shall be handled in accordance with the provisions of Article 172-1 of the Company Law, and the Board of Directors may not be included in the proposal. Shareholders may submit suggestive proposals to urge the Company to promote public interests or fulfill social responsibilities. In accordance with the relevant provisions of Article 172-1 of the Company Law, the proposal shall be limited to one item only; in addition, any proposal exceeding one item will not be included in the agenda.

Article 5-1 The agenda for the Shareholders' Meeting manual should include the following items and compile a table of contents and numbers:

1. Company name.
2. Year and type of Shareholders' Meeting.
3. Method of convening the Shareholders' Meeting.
4. Date of the Shareholders' Meeting.
5. Venue of the Shareholders' Meeting:
  - (1) For physical Shareholders' Meetings convened by the company, the venue of the Shareholders' Meeting shall be specified.
  - (2) For physical Shareholders' Meetings with video assistance (hereinafter referred to as video-assisted Shareholders' Meetings), in addition to specifying the venue of the physical Shareholders' Meeting, the video conferencing platform used for the video-assisted meeting shall also be specified.
  - (3) For Shareholders' Meetings held solely via video conferencing without a physical meeting (hereinafter referred to as virtual Shareholders' Meetings), the video conferencing platform used by the Company shall be specified.
6. Director Shareholding Status: In accordance with Article 26 of the Securities and Exchange Act, the minimum number of shares that all directors should hold, as well as the individual and collective shareholdings of directors recorded in the shareholders' register as of the cutoff date for share transfer suspension until the date of the shareholders' meeting.
7. Agenda.
8. Agenda items and proposers.
9. Rules and Procedures of Shareholders' Meeting, Articles of Incorporation, and other reference materials.

Article 5-2 The Company shall convene a shareholders' meeting and shall have the meeting agenda and supplementary materials prepared at least fifteen days prior to the meeting, available for shareholders to access at any time, and displayed at the company and its share transfer agent.

The meeting agenda and supplementary materials shall be made available for shareholders to access on the day of the shareholders' meeting in the following manner:

1. For physical Shareholders' Meetings, the Company shall distribute the meeting agenda and supplementary materials on-site at the Shareholders' Meeting venue.
2. For video-assisted Shareholder's Meetings, materials should be distributed at the venue of the Shareholders' Meeting and transmitted electronically to the video conference platform.
3. For virtual Shareholder's Meetings, materials should be transmitted electronically to the video conference platform.

The Company shall, at least twenty-one days before the Annual Shareholders' Meeting or fifteen days before the Extraordinary Shareholders' Meeting, produce electronic files of the Shareholders' Meeting agenda and the aforementioned supplementary materials and transmit them to the designated information disclosure website of the Company.

Article 6 The Company may designate lawyers, accountants or relevant personnel appointed by it to attend the Shareholders' Meeting.

The chairman may direct the pickets (or security personnel) to assist in maintaining order at the venue. When pickets (or security personnel) are present to help maintain order, they should wear armbands with the words "Pickets".

Article 7 The Company shall make continuous and uninterrupted audio and video recordings of the shareholder registration process, the meeting process, and the voting and counting process from the time of accepting shareholder registration, and preserve them for at least one year.

The vote-counting operation onto the resolution for vote or election made in the process of Shareholders' Meeting shall be done in a public place, and after the counting is completed, the voting results including the statistic weight shall be recorded and announced on the spot.

The Shareholder's Meeting in the process of electing directors shall observe the relevant election rules stipulated by the Company, and announce the election results on the spot, including the elected and lost director list, as well as their elected number of votes, respectively.

The ballots for the elections mentioned in the preceding paragraph shall be sealed and signed by the scrutineers, and shall be kept in a safe place for at least one year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recording shall be retained until the conclusion of the litigation.

- Article 8 The chairman shall call the Meeting to order at the appointed meeting time and disclose information concerning the number of nonvoting shares and number of shares represented by shareholders attending the meeting. If the attending shareholders do not represent a majority of the total number of issued shares, the chairman may announce a postponement, but no more than two such postponements, for a combined total of no more than one hour, may be made. If after two postponements the quorum is still not met and the attending shareholders represent less than one-third of the total number of issued shares, the chair shall declare the meeting adjourned. If after two postponements the quorum is still not met but the attending shareholders represent one-third or more of the total number of issued shares, a tentative resolution may be adopted in accordance with Article 175, Paragraph 1 of the Company Act.
- When, prior to conclusion of the meeting, the attending shareholders represent a majority of the total number of issued shares, the chairman may resubmit the tentative resolution for a vote by the Shareholders' Meeting pursuant to Article 174 of the Company Act.
- Article 9 If a Shareholders' Meeting is convened by the Board of Directors, the meeting agenda shall be set by the Board of Directors.
- The provisions of the preceding paragraph apply *mutatis mutandis* to a Shareholders' Meeting convened by a party with the power to convene that is not the Board of Directors.
- The chairman may not declare the meeting adjourned prior to completion of deliberation on the meeting agenda of the preceding two paragraphs (including extempore motions), except by a resolution of the Shareholders' Meeting.
- After the meeting adjourns, unless the chairman has violated the rules of procedure by prematurely adjourning the meeting, shareholders may not elect a new chairperson to continue the meeting either at the original venue or at another location.
- Article 10 Before speaking, an attending shareholder must specify on a speaker's slip the subject of the speech, his/her shareholder account number (or attendance card number), and account name. The order in which shareholders speak will be set by the chairman.
- A shareholder in attendance who has submitted a speaker's slip but does not actually speak shall be deemed to have not spoken. When the content of the speech does not correspond to the subject given on the speaker's slip, the spoken content shall prevail.
- When an attending shareholder is speaking, other shareholders may not speak or interrupt unless they have sought and obtained the consent of the chair and the shareholder that has the floor; the chairman shall stop any violation.
- Article 11 Each shareholder's speech on the same proposal shall not exceed five minutes each time. However, with the approval of the chairman, it can be extended once.
- If a shareholder's speech violates the provisions of the preceding paragraph or exceeds the scope of the topic, the chairman may intervene to halt their speech.
- Items not on the agenda shall not be discussed or put to a vote. During the discussion of agenda items, the chairman may declare the discussion closed at an appropriate time and, if necessary, may also declare the discussion suspended.
- Article 12 When a legal entity is entrusted to attend a Shareholders' Meeting, only one representative may be appointed by that legal entity to attend.
- If a legal entity shareholder appoints more than one representative to attend the Shareholders' Meeting, only one person may speak on the same agenda item.

- Article 13 After the speeches of the attending shareholders, the chairman may reply in person or by designating relevant personnel.
- Article 14 When the chairman considers that the discussion of the proposal has reached a level that can be voted on, he may announce the suspension of the discussion and put it to the vote.
- Article 15 The scrutiny and counting personnel for voting on proposals shall be designated by the chairman, but the scrutiny personnel shall have the status of shareholders. The voting results shall be reported on the spot and recorded.
- Article 16 During the meeting, the chairman may announce a break at a discretionary time.
- Article 17 Unless otherwise stipulated in the Company Act or the company's articles of association, the voting on the proposal shall be passed by a majority of the voting rights of the shareholders present. During voting, if the chairman solicits no objections from attending shareholders, the resolution is deemed passed, with its validity equivalent to that of a vote.  
This method of resolution, as mentioned above, involves the chairman soliciting shareholders' opinions. If there are no objections from the shareholders, it should be recorded as "Passed with no objections upon the chairperson's solicitation of all attending shareholders." However, if there are objections from the shareholders, the voting method and the number and proportion of votes in favor should be stated.
- Article 18 When there are amendments or substitutes for the agenda, the chairman shall determine the voting sequence along with the original agenda. If one of the agenda has already been passed, the other motions shall be considered rejected, and there is no need for further voting.
- Article 19 The resolutions of the shareholders' meeting shall be recorded in minutes, signed or sealed by the chairman, and distributed to all shareholders within 20 days after the meeting. The distribution of the meeting minutes may be done by announcement.  
Minutes of meetings shall be accurately recorded according to the date (year, month, day), venue, name of the chairman, resolution method, essentials of the proceedings and results of the meeting, and shall be kept permanently during the existence of the Company.
- Article 20 Matters not stipulated in these rules shall be handled in accordance with the Company Law and relevant laws and regulations.
- Article 21 The Rule shall come into force after being passed by the Shareholders' Meeting, and the same shall apply when they are revised.
- Article 22 The Rules was enacted on May 14, 2010.  
The first amendment was made on May 3, 2012.  
The second amendment was made on June 24, 2013.  
The third amendment was made on June 8, 2015.  
The fourth amendment was made on May 30, 2018.  
The fifth amendment was made on May 27, 2021.  
The sixth amendment was made on June 12, 2023.